A Open-label, Long-term Extension Study of KUC-7483 in Patients With Overactive Bladder.

Trial Profile

A Open-label, Long-term Extension Study of KUC-7483 in Patients With Overactive Bladder.

Withdrawn prior to enrolment
Phase of Trial: Phase III

Latest Information Update: 26 Jul 2010

At a glance

  • Drugs Ritobegron (Primary)
  • Indications Overactive bladder
  • Focus Adverse reactions
  • Sponsors Kissei Pharmaceutical
  • Most Recent Events

    • 26 Jul 2010 Status changed from recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 05 Nov 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top